<DOC>
	<DOCNO>NCT01028729</DOCNO>
	<brief_summary>This single arm study assess safety efficacy Endostar combine chemotherapy ( Gemcitabine plus Platinum-based chemotherapy ) follow Endostar maintenance therapy patient stage IIIB/IV non-small cell lung cancer ( NSCLC ) .</brief_summary>
	<brief_title>A Study Endostar Combined With Chemotherapy Followed Endostar Maintenance Therapy Treat Advanced Non-small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description>All eligible patient receive Endostar combination Gemcitabine plus Platinum-based chemotherapy 4 cycle ( 21 day cycle ) . Endostar treatment continue completion chemotherapy cycle disease progression . Efficacy evaluate every two cycle .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Endostatins</mesh_term>
	<criteria>Histological cytological diagnosis inoperable stage IIIB/IV NSCLC At least one measurable lesion Age 1875 year Life expectancy &gt; 3 month ECOG performance status 02 Adequate hematologic , renal , hepatic function Prior systemic chemotherapy NSCLC Evidence unstable disease ( serious infection , grade 4 hypertension , unstable angina , congestive heartfailure , compromise renal hepatic function , nonhealing wound bone fracture ) Concurrent anticoagulation therapy Evidence bleed diathesis coagulopathy Pregnant lactate woman Allergic E.coli preparation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2009</verification_date>
</DOC>